Core Insights - Celularity is collaborating with Genting Berhad to introduce placenta-derived allogeneic stem cell therapeutics in the Asia Pacific region [1][4] - Genting Berhad has commenced construction of Fontaine Vitale, a wellness and health center in Bali, Indonesia, which will utilize Celularity's products [1][2] - The Asia Pacific stem cell market is projected to grow from USD 3.0 billion in 2024 to USD 7.2 billion by 2030, with a CAGR of 16.4% [3] Company Overview - Celularity Inc. specializes in regenerative medicine, focusing on advanced biomaterial products and placenta-derived cell therapies targeting aging-related diseases, cancer, and immune disorders [5] - The company utilizes mesenchymal-like adherent stromal cells (MLASCs), CAR T-cells, and natural killer (NK) cells in its therapeutic programs [5] Market Context - The Asia Pacific region accounts for 16.8% of the global stem cell market and is expected to experience the highest growth rate globally [3] - Increased investment in stem cell technologies and therapies is driven by a growing emphasis on research and development in regenerative medicine within the region [3]

Core Viewpoint - Celularity Inc. has resolved its compliance issues with Nasdaq, allowing its stock to continue trading on the Nasdaq Stock Market after curing its filing delinquency [1][2][3] Group 1: Compliance Resolution - The Nasdaq Listing Qualifications Hearings Panel cancelled the scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) after the company filed its overdue quarterly reports [1][2] - Celularity filed its Form 10-Q for the period ended March 31, 2024, on October 16, 2024, and its Form 10-Q for the period ended June 30, 2024, on November 7, 2024, achieving compliance with Nasdaq requirements [2] Group 2: Company Statements and Challenges - Robert J. Hariri, CEO of Celularity, expressed satisfaction in meeting Nasdaq's requirements and emphasized the company's commitment to transparency and regulatory compliance [3] - The delays in filing were attributed to significant financial challenges in the biotechnology sector, which limited access to capital and affected the company's ability to secure essential audit and financial advisory services [3] Group 3: Company Overview - Celularity Inc. is focused on developing and commercializing advanced biomaterial products and placental-derived cell therapies targeting aging-related diseases, cancer, and immune disorders [4] - The company aims to leverage the unique biology of the placenta to create effective, accessible, and affordable therapeutic solutions for significant unmet global needs [4]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, $0.0001 par value per share CELU The Nasdaq Stock Market LLC Warrants, each exercisable for one-tenth of one share of Class A Common Stock at an exercise price of $11.50 per one-tenth of one share CELUW The Nasdaq Stock Market LLC FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38914 Celularity Inc. (Exact name of registrant as specified in its charter) Delaware 83-1702591 (State or other jurisdiction of ...

FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq Hearings Panel (the “Hearings Panel”) the Nasdaq Listing Qualifications Department’s determination regarding Celularity’s non-compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) and to seek an additional extension to regain compliance. As previously announced, Celularity received formal not ...

FLORHAM PARK, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company"), a regenerative medicine company developing and commercializing placental-derived technologies, today announced that it has received a formal notice from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on October 16, 2024, indicating that the Company is subject to delisting due to its inability to timely file its Forms 10-Q for the the periods ended March 31, 2024, and June 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38914 Celularity Inc. (Exact name of registrant as specified in its charter) Delaware 83-1702591 (State or other jurisdiction o ...

FLORHAM PARK, N.J., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it had added to its commercial portfolio of placental-derived advanced biomaterial products with the acquisition of Rebound, a full thickness placental-derived allograft matrix product, from Sequence LifeScience, Inc. ("Sequence"). "Rebound adds to our portfolio of placental-derived advanced biomaterial products, sales of which through the fi ...

FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright's 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024. H.C. Wainwright 26th Annual Globa ...

FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director a ...